NEUVIS Trademark

Trademark Overview


On Wednesday, July 31, 2019, a trademark application was filed for NEUVIS with the United States Patent and Trademark Office. The USPTO has given the NEUVIS trademark a serial number of 79268366. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Thursday, August 4, 2022. This trademark is owned by AusCann Group Holdings Ltd. The NEUVIS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for prevention, management or treatment of inflammatory disorders, neurological disorders, psychiatric disorders, malignancy, immune disorders, metabolic disorders, infectious diseases, gastrointestinal disorders, cardiovascular disorders, cancer, pain; Pharmaceutical preparations derived from natural sources namely, plants, herbs, and flowers for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, endometriosis, dementia, Alzheimer's disease, Parkinson's disease, gastrointestinal disorder, inflammatory bowel disease, Crohn's disease, ulcerative colitis, glaucoma, hypertension, anxiety, depression, stress, mood disorder, substance abuse, addiction, insomnia, sleep disorder, fatigue, eating disorder, appetite modification, muscle spasms, multiple sclerosis, muscle tension, tension, behavior modification, schizophrenia, bi-polar disorder, pain; Veterinary preparation...
neuvis

General Information


Serial Number79268366
Word MarkNEUVIS
Filing DateWednesday, July 31, 2019
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateThursday, August 4, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for prevention, management or treatment of inflammatory disorders, neurological disorders, psychiatric disorders, malignancy, immune disorders, metabolic disorders, infectious diseases, gastrointestinal disorders, cardiovascular disorders, cancer, pain; Pharmaceutical preparations derived from natural sources namely, plants, herbs, and flowers for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, endometriosis, dementia, Alzheimer's disease, Parkinson's disease, gastrointestinal disorder, inflammatory bowel disease, Crohn's disease, ulcerative colitis, glaucoma, hypertension, anxiety, depression, stress, mood disorder, substance abuse, addiction, insomnia, sleep disorder, fatigue, eating disorder, appetite modification, muscle spasms, multiple sclerosis, muscle tension, tension, behavior modification, schizophrenia, bi-polar disorder, pain; Veterinary preparations derived from natural sources namely, plants, herbs, and flowers for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, glaucoma, anxiety, appetite modification, muscle spasms, behavioural modification, pain; Plant extracts for medical, pharmaceutical and veterinary use; Biochemical and biological products, in the nature of terpenophenolics, terpenoids and flavones for medical and pharmaceutical use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, endometriosis, dementia, Alzheimer's disease, Parkinson's disease, gastrointestinal disorder, inflammatory bowel disease, Crohn's, ulcerative colitis, glaucoma, hypertension, anxiety, depression, stress, mood disorder, substance abuse, addiction, insomnia, sleep disorder, fatigue, eating disorder, appetite modification, muscle spasms, multiple sclerosis, muscle tension, tension, behavioural modification, schizophrenia, bi-polar, pain; Biochemical and biological products, namely, terpenophenolics, terpenoids and flavones for veterinary use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, glaucoma, anxiety, appetite modification, muscle spasms, behavioural modification, pain; Chemical preparations for medical and pharmaceutical use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, endometriosis, dementia, Alzheimer's disease, Parkinson's disease, gastrointestinal disorder, inflammatory bowel disease, Crohn's, ulcerative colitis, glaucoma, hypertension, anxiety, depression, stress, mood disorder, substance abuse, addiction, insomnia, sleep disorder, fatigue, eating disorder, appetite modification, muscle spasms, multiple sclerosis, muscle tension, tension, behavioural modification, schizophrenia, bi-polar, pain; Chemical preparations for veterinary use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, glaucoma, anxiety, appetite modification, muscle spasms, behavioural modification, pain; Chemical products, namely, aminoalkylindoles, 1,5-diarylpyrazoles, quinolines, arylsulfonamides, eicosanoids for medical and pharmaceutical use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, endometriosis, dementia, Alzheimer's disease, Parkinson's disease, gastrointestinal disorder, inflammatory bowel disease, Crohn's, ulcerative colitis, glaucoma, hypertension, anxiety, depression, stress, mood disorder, substance abuse, addiction, insomnia, sleep disorder, fatigue, eating disorder, appetite modification, muscle spasms, multiple sclerosis, muscle tension, tension, behavioural modification, schizophrenia, bi-polar, pain; Chemical products, namely, aminoalkylindoles, 1,5-diarylpyrazoles, quinolines, arylsulfonamides, eicosanoids for veterinary use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, glaucoma, anxiety, appetite modification, muscle spasms, behavioural modification, pain; Analgesic preparations; Anti-inflammatory preparations; Anti-microbial preparations for inhibiting microbiological growth and infection in medical and veterinary situations; Anti-nauseants treatment preparations; Anti-spasmodics; Anticonvulsants; Appetite stimulant preparations for medical purposes; Nausea medications, namely, nausea treatment preparations

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, October 4, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAusCann Group Holdings Ltd
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressAU

Trademark Events


Event DateEvent Description
Sunday, August 27, 2023FINAL DECISION TRANSACTION PROCESSED BY IB
Friday, August 4, 2023FINAL DISPOSITION NOTICE SENT TO IB
Friday, August 4, 2023FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Thursday, August 4, 2022ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Thursday, August 4, 2022ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Thursday, August 4, 2022ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Friday, January 21, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, January 21, 2022NON-FINAL ACTION E-MAILED
Friday, January 21, 2022NON-FINAL ACTION WRITTEN
Friday, October 15, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, October 14, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, October 14, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, April 14, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, April 14, 2021NON-FINAL ACTION E-MAILED
Wednesday, April 14, 2021NON-FINAL ACTION WRITTEN
Saturday, March 20, 2021NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Tuesday, March 9, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, March 9, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, March 9, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, March 3, 2021NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, March 3, 2021NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Saturday, September 26, 2020REFUSAL PROCESSED BY IB
Wednesday, September 9, 2020NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, August 28, 2020REFUSAL PROCESSED BY MPU
Saturday, July 25, 2020NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, July 24, 2020NON-FINAL ACTION WRITTEN
Friday, July 17, 2020ASSIGNED TO EXAMINER
Tuesday, November 5, 2019ASSIGNED TO EXAMINER
Friday, October 25, 2019ASSIGNED TO EXAMINER
Tuesday, October 8, 2019APPLICATION FILING RECEIPT MAILED
Friday, October 4, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, September 26, 2019SN ASSIGNED FOR SECT 66A APPL FROM IB